KalVista Pharmaceuticals, Inc. (KALV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.000.00%
Close 2026-06-12 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KALV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 287.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
KALV — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-06-11
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note and
Why it matters: KalVista needs to cut losses. This is important for its money situation after the buyout.
Worry ifOperating losses improve to less than -$20 million in Q2 2026.
Less concerning ifOperating losses worsen to more than -$30 million in Q2 2026.
Why it matters: Getting approval for kids helps EKTERLY reach more people. This can bring in more money.
Supportive ifEKTERLY gets approval for kids ages 2 to 11.
Worry ifEKTERLY's approval for kids is denied or delayed.
Why it matters: Working well with Chiesi is key for KalVista's future and EKTERLY's reach.
Watch forWatch for Chiesi shares good news on integration and positive feedback from HAE.
Also watch forWatch for Chiesi reports issues with integration and negative feedback from HAE.
Why it matters: Managing losses is critical for the company's financial health. It affects future funding.
Watch forOperating losses drop by 20% from the last quarter.
Also watch forOperating losses rise by 10% from the last quarter.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$103 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $564 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,258 loss on $10,000 · 32.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Regulatory issues can hurt how the company works. This can lower trust from investors.
Worry ifThe company corrects the delisting notice. It also follows the listing rules.
Less concerning ifMore regulatory actions could lead to a delisting from Nasdaq.
Why it matters: Strong revenue growth for EKTERLY shows demand for the treatment. This could boost Chiesi's rare disease portfolio.
Supportive ifEKTERLY revenue grows more than 20% compared to Q2 2026.
Worry ifEKTERLY revenue growth is less than 10% compared to Q2 2026.